Non-urothelial and urothelial variants of bladder cancer
- PMID: 36442362
- DOI: 10.1016/j.ctarc.2022.100661
Non-urothelial and urothelial variants of bladder cancer
Abstract
Non-urothelial bladder cancers make up a rare minority of all genitourinary (GU) tract histologic cancers since urothelial cancer (UC) makes up the most common histologic subtype. Bladder cancer variant histology (BCVH) or urothelial variants also occur rarely though distinction is important given aggressive presentation and natural history. While methods for diagnosis and treatment of typical urothelial cancers (UC) are well-established, there are no clear guidelines with regard to the diagnosis of non-urothelial bladder cancers, which often results in misdiagnosis and treatment delay. This review will focus on the clinicopathologic characteristics of the most common non-urothelial bladder cancers, to be distinguished from bladder cancer variant histology containing a UC component. The role of genomics in non-urothelial bladder cancers is evolving and the use of biomarkers to guide the diagnosis and treatment of these tumors remains a key area of unmet need. Treatment of these cancers will be discussed in a companion review.
Keywords: Adenocarcinoma; Bladder sarcomas; Carcinosarcomas; Non-urothelial bladder cancers; Squamous cell carcinoma.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest JAC serves on the Speakers’ Bureau of BMS, Astellas/SeaGen and Pfizer/EMD Serono. JAC serves on the Advisory Board of Exelixis, Immunomedics, AVEO Pharmaceuticals, Janssen, Pfizer/Myovant, Merck, AZD. The rest of the authors have no conflict to declare.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical